Skip to main content
Top
Published in: Drugs & Aging 6/2009

01-06-2009 | Original Research Article

Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US

An Analysis of National Survey Data

Authors: Pravin Kamble, Hua Chen, Jeffrey T. Sherer, Dr Rajender R. Aparasu

Published in: Drugs & Aging | Issue 6/2009

Login to get access

Abstract

Background

Atypical antipsychotic agents are increasingly being used for the treatment of behavioural and psychological symptoms of dementia. However, recent data suggest that the risk of adverse effects may offset the benefits of atypical agents in patients with dementia.

Objectives

To examine utilization of antipsychotic medications and the factors associated with use of atypical antipsychotics among elderly nursing home residents with dementia.

Methods

The study involved the analysis of prescription and resident files of a nationally representative sample of residents from the 2004 National Nursing Home Survey (NNHS). The study sample included an unweighted sample of 6103 elderly nursing home residents aged ≥65 years with dementia. The analysis focused on the use of six atypical antipsychotic agents and 11 typical agents. Descriptive weighted analysis was performed to examine the antipsychotic prevalence patterns in elderly nursing home residents with dementia. Multiple logistic regression analysis within the conceptual framework of Andersen’s Behavioural Model was used to examine the predisposing, enabling and need characteristics associated with use of atypical antipsychotics.

Results

According to the 2004 NNHS, the overall prevalence of dementia among elderly nursing home residents was 52.58%. Most of the elderly with dementia were female (77%), aged ≥85 years (56%), non-Hispanic (97%) and White (88%). Antipsychotic medications were taken by 32.88% of elderly patients with dementia. More elderly residents received atypical agents (31.63%) than typical agents (1.75%). Among the predisposing characteristics, the odds of receiving atypical antipsychotics were lower for females than males. The enabling factor facility bed capacity was significantly associated with use of atypical antipsychotics. Among the need characteristics, the likelihood of receiving atypical antipsychotic agents increased with dependence in decision-making ability, indicators of depressed mood and behavioural symptoms. The likelihood of receiving atypical antipsychotic agents decreased with increasing dependence for out-of-bed mobility and increased total activities of daily living. The odds of receiving atypical antipsychotic treatment increased with the diagnosis of schizophrenia, bipolar mania and anxiety among dementia patients.

Conclusion

Nearly one-third of elderly nursing home residents with dementia received antipsychotic medications, mainly atypical agents. Predisposing, enabling and need factors influenced the use of atypical agents in dementia patients. These findings suggest a need to optimize use of atypical antipsychotics in elderly dementia patients in nursing homes in the light of recent efficacy and safety data.
Literature
1.
go back to reference Agency of Healthcare Research and Quality. Efficacy and comparative effectiveness of off-label use of atypical anti-psychotics [publication no. 07-EHC003-EF]. Rockville (MD): Agency of Healthcare Research and Quality, 2007 Agency of Healthcare Research and Quality. Efficacy and comparative effectiveness of off-label use of atypical anti-psychotics [publication no. 07-EHC003-EF]. Rockville (MD): Agency of Healthcare Research and Quality, 2007
2.
go back to reference Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRef Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRef
3.
go back to reference Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Gerontologist 2000; 40: 663–72PubMedCrossRef Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Gerontologist 2000; 40: 663–72PubMedCrossRef
4.
go back to reference Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study. J Clin Epidemiol 2002; 55:462–8PubMedCrossRef Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study. J Clin Epidemiol 2002; 55:462–8PubMedCrossRef
5.
go back to reference Margallo-Lana M, Swann A, O’Brian J, et al. Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int JGeriatr Psychiatry 2001; 16: 39–44CrossRef Margallo-Lana M, Swann A, O’Brian J, et al. Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int JGeriatr Psychiatry 2001; 16: 39–44CrossRef
6.
go back to reference Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1991; 3: 371–6PubMed Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1991; 3: 371–6PubMed
7.
8.
go back to reference Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMed Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMed
9.
go back to reference Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59(10): 550–61PubMedCrossRef Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59(10): 550–61PubMedCrossRef
10.
go back to reference Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61Suppl. 8: 5–11PubMed Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61Suppl. 8: 5–11PubMed
11.
go back to reference Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRef Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRef
12.
go back to reference Jeste DV, Lacro JP, Bailey A, et al. Incidence of tardive dyskinesia with risperidone versus haloperidol in older patients. J Am Geriatr Society 1999; 47: 716–9 Jeste DV, Lacro JP, Bailey A, et al. Incidence of tardive dyskinesia with risperidone versus haloperidol in older patients. J Am Geriatr Society 1999; 47: 716–9
13.
go back to reference Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000 Jul; 157(7): 1150–5PubMedCrossRef Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000 Jul; 157(7): 1150–5PubMedCrossRef
14.
go back to reference Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972–82PubMedCrossRef Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972–82PubMedCrossRef
15.
go back to reference Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35(3): 187–91PubMedCrossRef Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35(3): 187–91PubMedCrossRef
16.
go back to reference Verma SD, Davidoff DA, Kambhampati KK. Management of the agitated elderly patients in the nursing homes: the role of the atypical antipsychotics. J Clin Psychiatry 1998; 59(19): 50–5PubMed Verma SD, Davidoff DA, Kambhampati KK. Management of the agitated elderly patients in the nursing homes: the role of the atypical antipsychotics. J Clin Psychiatry 1998; 59(19): 50–5PubMed
17.
go back to reference Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61(14): 49–51PubMed Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61(14): 49–51PubMed
18.
go back to reference Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75–8PubMedCrossRef Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75–8PubMedCrossRef
21.
go back to reference Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRef Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRef
22.
go back to reference Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; CD003476 Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; CD003476
23.
go back to reference Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43PubMedCrossRef Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43PubMedCrossRef
24.
go back to reference Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res 2006; 55(4): 252–8PubMedCrossRef Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res 2006; 55(4): 252–8PubMedCrossRef
25.
go back to reference Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community dwelling and institutionalized Medicare beneficiaries. Am Geriatric Soc 2007; 55: 1508–16CrossRef Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community dwelling and institutionalized Medicare beneficiaries. Am Geriatric Soc 2007; 55: 1508–16CrossRef
27.
go back to reference Koch H, Cambell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 1982; 2: 1–90 Koch H, Cambell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 1982; 2: 1–90
29.
go back to reference Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973; 51: 95–124PubMedCrossRef Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973; 51: 95–124PubMedCrossRef
30.
go back to reference Gray SL, Hanlon JT, Fillenbaum GG, et al. Predictors of nutritional supplement use by the elderly. Pharma-cotherapy 1996; 16(4): 715–20 Gray SL, Hanlon JT, Fillenbaum GG, et al. Predictors of nutritional supplement use by the elderly. Pharma-cotherapy 1996; 16(4): 715–20
31.
go back to reference Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003; 51: 671–7PubMedCrossRef Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003; 51: 671–7PubMedCrossRef
32.
go back to reference Liperoti R, Mor V, Lapane K, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106–12PubMedCrossRef Liperoti R, Mor V, Lapane K, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106–12PubMedCrossRef
33.
go back to reference Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66(9): 1090–6PubMedCrossRef Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66(9): 1090–6PubMedCrossRef
34.
go back to reference Sorensen L, Foldspang A, Gulmann N, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2000; 16(2): 147–54CrossRef Sorensen L, Foldspang A, Gulmann N, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2000; 16(2): 147–54CrossRef
35.
go back to reference Hien L, Cumming R, Cameron I, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53(8): 1290–5CrossRef Hien L, Cumming R, Cameron I, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53(8): 1290–5CrossRef
36.
go back to reference Frenchman BI. Atypical antipsychotics for nursing home patients a retrospective chart review. Drugs Aging 2005; 22(3): 257–64PubMedCrossRef Frenchman BI. Atypical antipsychotics for nursing home patients a retrospective chart review. Drugs Aging 2005; 22(3): 257–64PubMedCrossRef
37.
go back to reference Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167: 676–83PubMedCrossRef Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167: 676–83PubMedCrossRef
38.
go back to reference Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003; 18: 511–9PubMedCrossRef Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003; 18: 511–9PubMedCrossRef
39.
go back to reference Sclar DA, Robison LM, Gavrun C, et al. Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor? Gen Hosp Psychiatry 2008; 30: 73–6PubMedCrossRef Sclar DA, Robison LM, Gavrun C, et al. Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor? Gen Hosp Psychiatry 2008; 30: 73–6PubMedCrossRef
40.
go back to reference McLaughlin T, Geissler EC, Wan GJ. Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy 2003; 23(10): 1251–6PubMedCrossRef McLaughlin T, Geissler EC, Wan GJ. Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy 2003; 23(10): 1251–6PubMedCrossRef
41.
go back to reference Tour TL, Brandt NJ, Limcangco MR, et al. Impact of second-generation antipsychotics on the use of anti-parkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother 2006; 4(1): 25–35CrossRef Tour TL, Brandt NJ, Limcangco MR, et al. Impact of second-generation antipsychotics on the use of anti-parkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother 2006; 4(1): 25–35CrossRef
43.
go back to reference Buchanan RJ, Wang S, Ju H, et al. Analyses of gender differences in profiles of nursing home residents with Alzheimer’s disease. Gend Med 2001; 1: 48–59CrossRef Buchanan RJ, Wang S, Ju H, et al. Analyses of gender differences in profiles of nursing home residents with Alzheimer’s disease. Gend Med 2001; 1: 48–59CrossRef
44.
go back to reference Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000; 38(12): 1164–73PubMedCrossRef Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000; 38(12): 1164–73PubMedCrossRef
Metadata
Title
Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US
An Analysis of National Survey Data
Authors
Pravin Kamble
Hua Chen
Jeffrey T. Sherer
Dr Rajender R. Aparasu
Publication date
01-06-2009
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2009
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200926060-00005

Other articles of this Issue 6/2009

Drugs & Aging 6/2009 Go to the issue

Original Research Article

“I Just Take What I Am Given”

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.